S tatins (HMG-CoA reductase inhibitors) are the most prescribed class of lipid-lowering drugs used in the treatment and prevention of cardiovascular disease. 1,2 Despite reducing clinical cardiovascular events by 20% to 50% 3 and having a positive benefit to risk ratio, statins are underused 4,5 because they can cause muscular side effects ranging from nonspecific myalgia to rhabdomyolysis. 6 The frequency of muscle symptoms was evaluated at 10.5% in the Prediction of Muscular Risk in Observational Conditions (PRIMO) study, an observational study in an unselected hyperlipidemic patient population receiving high-dose statins. 7 Many patients stop statin therapy for aches and pains that are mistakenly thought to be related to their medication, which underscores the relevance of research aiming at the refinement of clinical tools used for the diagnosis of statin-induced myotoxicity.
the genetic factors involved in population CK levels, let alone in a statin-medicated population. In this study, we tested for genetic factors associated with serum CK levels in a white population of statin users with and without muscle symptoms. We conducted a discovery genome-wide association study (GWAS) for serum CK levels using samples from a case-control cohort of statin-induced myopathy. Top hits were replicated using the Montreal Heart Institute (MHI) Biobank data.
Methods

Study Populations
The discovery cohort is based on a secondary phenotype analysis of an existing case-control study for statin-induced myopathy. The statin case-control study includes 4679 patients recruited in 9 clinical centers throughout the province of Quebec (Canada). The research protocol was approved by the recruiting sites' ethics committees, and all human participants gave written informed consent. Cases had documented statinrelated muscle symptoms that disappeared on withdrawal or reduction in dosage or clearly appeared to be statin-related in the opinion of the physician (additional information in the Data Supplement). Controls had dyslipidemia treated with a stable and at least moderate dose of a statin (eg, atorvastatin ≥20 mg, rosuvastatin ≥20 mg, simvastatin ≥40 mg, or pravastatin ≥40 mg) for ≥3 months and had never experienced statinrelated side effects. Participants were excluded if they presented with hypothyroidism that is not controlled with a stable dose of supplement for at least the last 3 months; known hyperthyroidism in the last year; history of alcohol or drug abuse in the last year; known renal insufficiency with serum creatinine level of 200 μmol/L or more at the time of recruitment; known severe liver disease with cirrhosis, biliary obstruction, acute or chronic infectious hepatitis at the time of recruitment; known hereditary or acquired muscle disease; any medical or psychiatric condition that may make the patient an unsuitable candidate for the study in the physician's opinion; participation in any investigational drug study within 30 days of recruitment. Serum CK level was measured at the time of recruitment into the study. The analysis of the case-control study is underway and results will not be presented here. In this study, we are interested in conducting a secondary phenotype analysis of CK levels with the statin case-control samples. As such, we excluded 954 cases who were not taking a statin at the time of recruitment and 25 subjects because of missing CK measurements or because they had been recruited into the study because of high CK level. There remained 3412 samples for the secondary phenotype analysis of serum CK levels, including 2150 controls (without muscle pain), 814 cases with ongoing pain at the time of recruitment, and 448 cases who had experienced muscle pain in the past but did not have pain at the time of recruitment.
For the replication cohort, we relied on the MHI Biobank. The research protocol was approved by the MHI ethics committee, and all patients provided informed consent. This is a longitudinal hospital cohort of patients recruited from different departments at the MHI. Statin use and dose were documented at recruitment. For each participant, the most recent CK measure from the hospital records before cohort entry was used, excluding CK measurements taken while patients were hospitalized, from emergency visits, from the dialysis clinic, from patients who took part in the discovery cohort and from patients with documented renal impairment (creatinine level >200 μmol/L); 5391 unrelated and white participants were genotyped.
Genotyping
Whole-genome analysis was performed with 620 901 single nucleotide polymorphisms (SNPs) using the Illumina Infinium HD Assay and the Human 610quad BeadChips (Illumina, San Diego, CA). In complement, a Multi-Sample iSelect Custom BeadChip was used, containing 11 568 SNPs from candidate genes involved in lipid homeostasis, hypertension, and drug metabolism. Control samples provided 100% consistency. After genotype quality procedures (in the Data Supplement) and removal of 65 nonwhite samples, there remained 584 509 SNPs for analysis and 4391 samples from the case-control statin study.
For the replication study with the MHI Biobank samples, 5330 individuals were successfully genotyped for the top 3 discovery SNPs. A single Sequenom panel was designed and validated using HapMap DNA samples. The Sequenom MassArray Maldi-TOF System (Sequenom, La Jolla, CA) was used with Sequenom's Typer 4.0.22 Software. Each plate was clustered using autocluster and manually inspected. Two Coriell Institute DNA samples (NA11993 and NA07357) used as controls on each genotyping plate showed 100% concordance on all plate replicates and 100% concordance of genotype calls with expectations for corresponding SNPs in the 1000 Genomes and HapMap reference database. All genotyping was performed at the Beaulieu-Saucier Pharmacogenomics Center. Additional methods are described in the Data Supplement.
Imputation
We used the program IMPUTE2 18 to impute the discovery data set using reference data sets from the filtered SNPs of the CEU population from including HapMap and 1000 genomes project reference files. Strand alignment was solved by automatically flipping non A/T and C/G SNPs according to position. Ambiguous A/T and C/G SNPs were considered missing and were imputed. We used 568 969 study SNPs, 1 385 414 HapMap SNPs, and 7 611 062 SNPs from the 1000 genomes project. Imputed SNPs with genotype probabilities ≥90% and completion rates of 98% or higher were retained, leaving 3 232 779 SNPs for genome-wide analysis.
Statistical Analysis
Statistical tests performed on genetic data were 2-sided and thresholdadjusted for the multiple testing of SNPs. The genome-wide significance threshold of P<5×10 −8 was used for the discovery GWAS. 19 Serum CK levels were log-transformed to achieve normality. We used a general linear model to test the association of genetic markers with CK levels. Outliers for CK measures were detected using studentized residuals based on the general linear model model with selected covariates (3 samples were excluded in the discovery set). For the discovery GWAS analysis, adjustment was made for case-control recruitment status to control for sampling bias, for principal components 1 and 2 to control for confounding by population stratification and for age, sex, testing site, physical activity level (mild/moderate/active), and body mass index to control for modifiers of serum CK levels. For the replication analysis in the MHI Biobank samples, adjustment was made for age, sex, and body mass index. The 1-degree of freedom additive genetic test was used for genotypes coded as 0, 1, or 2 according to the number of copies of the minor allele.
Reported P values correspond to the likelihood ratio test of the genotype effect, where H 0 : β=0 for the additive genetic effect. Dosage data of imputed SNPs were tested within a regression framework with PLINK software, which may use different reference alleles. We have also conducted the analysis of imputed SNPs of interest by fixing the most likely genotypes for analysis within a general linear model regression model as for the genotyped SNPs. Although the main model made an adjustment for the case-control status, we further explored the possible effect of the sampling group (all cases, cases with pain, cases without pain, and controls) on the association of the significantly associated SNPs with CK levels by testing the genetic association in separate subgroups for the sampling group, with and without the presence of covariates. For those analyses, we fixed the imputed alleles of SNP rs56158216 in the MARK4 gene for genotypes with imputed probabilities of ≥0.9. This provided artificially fixed genotype data for 3347 individuals in the discovery population. The effect of statin dose equivalent and statin use duration on the association of the significantly associated SNPs with CK levels was evaluated by adding the 2 additional covariates individually and in combination to other covariates to the model of CK level in the discovery population, and the interaction effect with the genetic variants was evaluated.
Additional analytic methods are described in the Data Supplement.
Results
Clinical Characteristics
Patients taking part of the discovery GWAS with on-statin CK serum levels had a mean age of 62 years, were mostly December 2014 men (72%) and self-identified as whites (100%). The most frequently used statin was atorvastatin (57%) followed by rosuvastatin (24%). As cases had documented statin-induced muscle symptoms, they were put on lower statin doses and on alternative statin treatment choices, as seen in the lower mean statin dose (P=3.39×10 −44 ) and lower rate of atorvastatin users (41%) in cases as compared with controls (68%). Patients with ongoing muscle pain presented with slightly higher mean serum CK levels (129.7±108.4 U/L) than those with a prior history of statin-induced pain (117.1±73.0 U/L) and controls tolerating well statins (115.8±93.7 U/L). In a multiple regression analysis, when adjusting for factors influencing CK levels, including age, sex, body mass index, and physical activity, we saw a significant difference in CK levels between cases and controls (P=7.25×10 −7 ), despite the fact that the majority of CK values were within the normal clinical range. Indeed, only 2 (0.25%) of on-statin patients with ongoing muscle pain had CK values above 3× the upper limit of normal compared with 2 (0.09%) of controls (Table 1) .
Discovery GWAS
The GWAS for circulating CK levels was conducted as a secondary phenotype analysis of the case-control study of statin-induced myopathy with 3412 statin users, including 1262 cases with ongoing or past statin-related muscle symptoms and 2150 without. Three SNPs had results passing the significance threshold of 5×10 −8 : rs56158216 in the MARK4 gene (P=1.77×10 −13 ; R 2 =0.010; minor allele frequency, 0.01), Tables 2 and 3 ). All 3 SNPs are located on chromosome 19, at position 45 767 997 (build 37) for rs56158216, which a synonymous SNP in exon 5 of MARK4; at position 45 821 183 for rs11559024 which is a nonsynonymous variant in exon 3 of CKM; and at position 54 753 543 for rs2361797 which is located upstream of gene LILRB5. Rs56158216 in MARK4 is an imputed SNP in linkage disequilibrium with rs11559024 in CKM (r 2 =0.676, D′=0.847), and rs2361797 in LILRB5 is not in linkage disequilibrium with either of the other 2 SNPs (r 2 =0, D′<0.1). We conducted a second pass GWAS by further conditioning on the rs11559024 (CKM) and rs2361797 (LILRB5) and found no additional SNPs passing the genomewide significance threshold and none on chromosome 19 provided P<10 −5 .
When testing for association of the 3 SNPs with serum CK levels in the cases and controls separately, we can see that the association is strongest in the control group (Tables 2 and 3 (Tables 2 and 3 ). We tested for association of the genetic variants with the case-control status alone and in the presence of the modeled covariates and found no association (P<0.05).
Overall, carriers of 1 copy of the rare allele at rs11559024 in CKM (AG) had a mean (±SD) in CK level of 68.13 (±35.57) U/L, compared with 119.32 (±84.74) U/L for homozygotes for the common allele (AA; Table 4 ). At SNP rs56158216 of the MARK4 gene, carriers of 1 copy of the rare allele (TC) had a mean in CK level of 72.91 (±32.04) U/L, compared with 118.94 (±82.73) U/L for homozygotes for the common allele (CC). For rs2361797 in LILRB5, homozygotes for the minor allele (TT) had a mean CK level of 129.51 (±92.57) U/L compared with 111.55 (±83.63) U/L for homozygotes of the common allele (CC) ( Table 4 ). Carriers of the G allele at rs11559024 in CKM were more frequent in the lowest tertile of CK values, 67% (48/71), compared with 6% (4/71) in the upper tertile (Table III in Position in NCBI build 37; Alleles: minor/major alleles; β is the regression parameter for allelic effect of the genetic term coded as 0, 1, and 2 for the number of minor allele by genotype; P value is for the genetic term in a multiple regression equation; GWAS analysis is adjusted for 2 principal components for genetic ancestry, case-control myotoxicity status, age, sex, sampling site, physical activity level, and body mass index. CK indicates creatine kinase; GWAS, genome-wide association study; MAF, minor allele frequency; R 2 , coefficient of determination for the genetic term alone in a simple linear regression; SE, standard error of β; and SNP, single nucleotide polymorphisms. *Imputed SNP analyzed by dosage in PLINK software making use of minor allele as reference allele. †Imputed SNP analyzed in general linear model by fixing the most likely alleles. December 2014
To investigate the effect of statin dose and statin use duration on the genetic associations with each of the top SNP, those variables were added independently to the multivariate model of CK in the presence of the covariates from the main model. Statin dose or statin use duration added no additional information to this model, were not statistically significant and their interaction effect with the genetic variants were not significant. Nonlinear association by generalized additive modeling of rs86158216, rs2361797, and rs11559024 were nonsignificant.
Replication Analysis
Replication of the association signal of the statistically significant SNPs in the MARK4, CKM, and LILRB5 genes was evaluated by genotyping the SNPs in 5330 participants to the MHI Biobank. In a model that adjusted for age, sex, and body mass index, all 3 SNPs were significantly associated with P<5×10 −8 ( Table 5) . When restricting the analysis to statin users (n=3389), association was detected with rs56158216 in the MARK4 gene (P=4.22×10 −14 ; R 2 =0.015), rs11559024 (P=4.32×10 −16 ; R 2 =0.017) in the CKM gene, and rs2361797 (P=4.45×10 −10 ; R 2 =0.010) in the LILRB5 gene. The association was similarly strong in statin nonusers (n=1941) for all 3 SNPs with similar effect sizes, as well as in the combined set with rs56158216 (P=1.12×10 −18 ; R 2 =0.013) in the MARK4 gene, rs11559024 (P=1.19×10 −21 ; R 2 =0.015) in the CKM gene, and rs2361797 (P=1.79×10 −17 ; R 2 =0.013) in the LILRB5 gene (Table 5 ). Rs56158216 in MARK4 was in linkage disequilibrium with rs11559024 in CKM (r 2 =0.728, D′=0.886), and rs2361797 in LILRB5 was not in linkage disequilibrium with either of the other 2 SNPs (r 2 <0.01, D′<0.2). In a regression model of CK, when including covariates and conditioning for the rs11559024 CKM variant, the MARK4 SNP rs56158216 lost its association signal (P=0.1874).
The genetic variants in the CKM and LILRB5 gene were found to contribute independently to serum CK levels. In the MHI Biobank, the CKM rs11559024 variant could explain alone 1.7% of the interindividual variability in CK levels in the 3389 statin users and 1.2% in 1941 statin nonusers; and the LILRB5 rs2361797 could explain 1.0% in of the variability in CK levels in statin users and 1.7% in statin nonusers.
Discussion
In this study, we demonstrate that the serum CK level is associated with genetic variants in the CKM and LILRB5 genes of statin users. The replication study has allowed the demonstration of their association in statin nonusers as well. In the discovery cohort, variant rs11559024 in the CKM gene (Glu83Gly) was significantly associated with CK levels of statin users (P=3.69×10 −16 ; R 2 =0.018): carriers of the minor allele (AG) had mean CK levels of 68.1±35.6 U/L, whereas homozygote carriers of the major allele (AA) had values of 119.3±84.7 U/L. The minor allele has a frequency of 1% and we did not find homozygote carriers of the minor allele. This variant was also associated with CK levels in statin users of the replication cohort (P=4.32×10 −16 ; R 2 =0.02) and the effect was also observed in nonusers of statins from the MHI Biobank (P=4.08×10 −7 ; R 2 =0.02). This missense variant was predicted as highly deleterious as it is located on the protein surface. [20] [21] [22] A rare synonymous coding SNP (rs56158216; minor allele frequency, 1%) located in exon 5 of MARK4 was found to Position in NCBI build 37; β is the regression parameter for allelic effect of the genetic term coded as 0, 1, and 2 for the number of minor allele by genotype; SE, standard error of β; P value is for the genetic term in a multiple regression equation; an analysis is adjusted for 2 principal components for genetic ancestry, age, sex sampling site, physical activity level, and body mass index. GWAS indicates genome-wide association study; and SNP, single nucleotide polymorphisms.
*Imputed SNP analyzed in general linear model by fixing the most likely alleles. be in linkage disequilibrium with rs11559024 in CKM (r 2 =0.7). The association signal at the MARK4 variant disappeared (P < 0.1) when tested for association in the presence of the CKM variant, supporting the notion that it is the CKM variant that is leading the association with CK levels and not the MARK4 variant. CK catalyzes the reversible transfer of high energy phosphates between ATP/ADP and creatine systems. CK is important for normal energy homeostasis and exerts several integrated functions, including temporary energy buffering, metabolic capacity, energy transfer, and metabolic control. CK level and activity are clinically important and CK serves as a reliable biomarker for several diseases, including myocardial infarction, rhabdomyolysis, muscular dystrophy, and autoimmune myositis. There is only limited documentation of polymorphisms in the CKM gene in the literature. 23, 24 Wu et al have reported on the finding of the point mutation E79G in CKM in 2 acute myocardial infarction patients with muscle CK activity deficiency. 24 This variant is situated 12 base pairs upstream from variant rs11559024 (Glu83Gly) reported in our study.
In the discovery cohort, statin users also had significantly different levels of CK between genotype groups of SNP rs2361797 (P=1.96×10 −10 ), an SNP located upstream of the LILRB5 gene. Homozygous carriers (TT) of the minor allele at rs2361797 had higher levels of CK (129.5±92.6 U/L) compared with homozygous carriers of the major allele (CC; 111.6±83.6 U/L). The SNP was not in linkage disequilibrium with the CKM gene variant (r 2 <0.01). The minor allele had a frequency of 44%, and heterozygote carriers had a mean level of CK that was intermediate between those of the homozygotes. The association was replicated in the MHI Biobank, in statin users (P=4.45×10 −10 ; R 2 =0.010) and nonusers (P=3.17×10 −9 ; R 2 =0.017).
LILRB5 is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. 25 Leukocyte immunoglobulin-like receptor subfamily B receptors are expressed on immune cells where they bind to MHC class I molecules on antigen-presenting cells and inhibit stimulation of an immune response. The protein is an integral membrane protein with receptor activity and contains 4 extracellular immunoglobulin-like domains. The protein also includes 2 immunoreceptor tyrosine-based inhibition motifs and 3 phosphorylation sites in its cytoplasmic part. 26 The LILRB5 gene presents multiple transcript variants encoding different isoforms and is highly expressed in skeletal muscle, liver, and gallbladder. 27 Mass spectrometry has detected the protein in plasma, liver, and aorta and this plasmatic protein has been ascertained in the HUPO plasma proteome project. 27, 28 Furthermore, we could not find evidence of LILRB5 modulation by statins. 29 There was no report in the literature until our work for possible implication of this gene in human disease, but the implication of immunity in interindividual variation in CK is not entirely new. Interindividual variability in CK levels is influenced by the rate of CK leakage from injured muscle fibers into the circulation but it is possible that a portion of the variability is also because of the rate of CK clearance from the circulation. [30] [31] [32] CK clearance occurs via the mononuclear phagocytic system in the liver and via Fc receptors that mediate the endocytosis of immune complexes. CK immune complexes are found in the blood and are commonly referred to as macro CK type 1, which is a complex formed by an immunoglobulin, often immunoglobulin G, and a CK isoenzyme, often CK-BB. 30, 33 LILRB5 variant rs2361797 is an eQTL that has been shown to also have trans effects to the neighboring genes LILRB3, LILRA6, LILRB2, and TSEN34. 34 The discovery study was, in part, limited by its reliance on a secondary phenotype analysis approach to the identification of genetic determinants of circulating CK levels. Because cases and controls are selected at different rates, the sample does not constitute a random sample of the general population. As a result, the association tests between the SNPs and CK levels as secondary trait could be distorted in the case-control sample. To our benefit, the sampling rates were not dramatically different, as cases are not rare, and represent 10% of all statin users. We have excluded 954 participants to the discovery cohort who were past-sufferers of statin-induced myotoxicity and were no longer on statin medication. This could have depleted the sample from the most extreme on-statin CK measures. The MHI Biobank is, however, a representative sample of prevalent statin users, and the strong replication of the genetic association signals in this cohort adds considerable support to the discovery. Although CK was measured on all participants of the discovery cohort at study entry, we had to rely on convenience measures of CK available from hospital records of participants to the MHI Biobank for the replication study. This could add variability in the measure of CK because some measures may have been obtained during acute illness. The discovery study was well powered (80%) to detect genetic determinants of CK levels with effect sizes of R 2 ≥0.014 for a genetic variant with 1% allele frequency, and R 2 ≥0.011 for 44% allele frequency. The GWAS was limited to a low-density chip of 600 000 SNPs but with enrichment for selected genetic variants, which proved to be a valuable addition as no other CKM gene variants were detected.
Overall, we have identified genetic variants in 2 genes (CKM and LILRB5) that are likely regulators of serum concentrations of CK in statin users and nonusers. Each of the genetic variants identified could explain ≈1% of the interindividual variation in CK in the discovery cohort and in the MHI biobank cohort. P value is for the genetic term in a multiple regression with adjustment for age, sex, and body mass index . MAF indicates minor allele frequency estimated in Biobank samples; MHI, Montreal Heart Institute; and R 2 , the coefficient of determination for the genetic term alone in a simple linear regression.
